RecruitingPHASE2, PHASE3NCT07532603
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
Studying Graham Little-Piccardi-Lassueur syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Priovant Therapeutics, Inc.
- Intervention
- Oral Brepocitinib(drug)
- Enrollment
- 342 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2029
Study locations (5)
- Clinical Trial Site, Phoenix, Arizona, United States
- Clinical Trial Site, Portland, Oregon, United States
- Clinical Trial Site, Smyrna, Tennessee, United States
- Clinical Trial Site, Austin, Texas, United States
- Clinical Trial Site, Cedar Park, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07532603 on ClinicalTrials.gov